58 companies

Anbio Biotechnology

Market Cap: US$2.1b

Provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally.

New

NNNN

US$47.68

7D

8.2%

1Y

n/a

Qiagen

Market Cap: US$10.4b

Provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally.

QGEN

US$48.97

7D

-2.0%

1Y

3.7%

Stevanato Group

Market Cap: US$6.0b

Engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

STVN

US$21.83

7D

-5.5%

1Y

5.5%

Vaxcyte

Market Cap: US$3.9b

A clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.

PCVX

US$30.00

7D

-9.1%

1Y

-61.0%

Corcept Therapeutics

Market Cap: US$7.6b

Engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

CORT

US$73.59

7D

4.5%

1Y

115.6%

ACADIA Pharmaceuticals

Market Cap: US$4.2b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

ACAD

US$25.45

7D

7.7%

1Y

61.8%

Exelixis

Market Cap: US$10.1b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

EXEL

US$37.95

7D

1.3%

1Y

42.1%

Biogen

Market Cap: US$18.8b

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.

BIIB

US$128.93

7D

-3.0%

1Y

-36.8%

ADMA Biologics

Market Cap: US$3.9b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

ADMA

US$16.76

7D

-11.6%

1Y

-3.0%

United Therapeutics

Market Cap: US$13.6b

A biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.

UTHR

US$301.39

7D

-1.1%

1Y

-6.9%

IDEAYA Biosciences

Market Cap: US$2.0b

A precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

IDYA

US$23.59

7D

-2.2%

1Y

-38.2%

Kiniksa Pharmaceuticals International

Market Cap: US$2.4b

A biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide.

KNSA

US$32.78

7D

-0.9%

1Y

27.4%

Regeneron Pharmaceuticals

Market Cap: US$56.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

REGN

US$556.56

7D

-2.3%

1Y

-52.0%

Catalyst Pharmaceuticals

Market Cap: US$2.4b

A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.

CPRX

US$20.34

7D

-8.5%

1Y

3.8%

Apogee Therapeutics

Market Cap: US$2.0b

A clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other inflammatory and immunology indications.

APGE

US$36.70

7D

-4.3%

1Y

-17.4%

Incyte

Market Cap: US$15.5b

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.

INCY

US$81.61

7D

5.0%

1Y

31.6%

Xenon Pharmaceuticals

Market Cap: US$2.6b

A neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.

XENE

US$35.99

7D

4.6%

1Y

-7.2%

Neurocrine Biosciences

Market Cap: US$12.3b

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.

NBIX

US$128.89

7D

0.4%

1Y

-14.5%

Bio-Techne

Market Cap: US$7.9b

Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.

TECH

US$52.83

7D

-3.3%

1Y

-28.1%

Supernus Pharmaceuticals

Market Cap: US$2.3b

A biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States.

SUPN

US$41.24

7D

9.9%

1Y

22.6%

Summit Therapeutics

Market Cap: US$21.0b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

SMMT

US$25.69

7D

-11.8%

1Y

128.3%

Ligand Pharmaceuticals

Market Cap: US$2.9b

A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.

LGND

US$152.69

7D

13.0%

1Y

48.2%

Denali Therapeutics

Market Cap: US$2.0b

A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.

New

DNLI

US$13.22

7D

-7.5%

1Y

-42.6%

Vertex Pharmaceuticals

Market Cap: US$96.0b

A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF).

VRTX

US$387.77

7D

3.4%

1Y

-17.1%

Harmony Biosciences Holdings

Market Cap: US$2.0b

A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

New

HRMY

US$35.47

7D

1.5%

1Y

1.1%

Viking Therapeutics

Market Cap: US$4.3b

A clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

VKTX

US$39.86

7D

17.1%

1Y

-29.1%

Krystal Biotech

Market Cap: US$4.0b

A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.

KRYS

US$143.62

7D

4.6%

1Y

-23.4%

BioMarin Pharmaceutical

Market Cap: US$10.9b

A biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

BMRN

US$56.86

7D

-8.2%

1Y

-37.5%

West Pharmaceutical Services

Market Cap: US$17.3b

Designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.

WST

US$239.90

7D

0.4%

1Y

-18.8%

Veracyte

Market Cap: US$2.2b

Operates as a diagnostics company in the United States and internationally.

New

VCYT

US$28.77

7D

15.0%

1Y

-11.6%

Metsera

Market Cap: US$3.2b

A clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.

MTSR

US$30.88

7D

-7.4%

1Y

n/a

Avidity Biosciences

Market Cap: US$5.9b

A biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs).

RNA

US$46.23

7D

20.8%

1Y

2.8%

Natera

Market Cap: US$21.6b

A diagnostics company, provides molecular testing services worldwide.

NTRA

US$159.81

7D

14.1%

1Y

34.3%

Ocular Therapeutix

Market Cap: US$2.2b

A biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.

New

OCUL

US$12.48

7D

4.0%

1Y

55.9%

Protagonist Therapeutics

Market Cap: US$3.3b

A biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases.

PTGX

US$54.53

7D

1.2%

1Y

35.3%

Alkermes

Market Cap: US$4.4b

A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

ALKS

US$27.43

7D

3.1%

1Y

3.8%

Page 1 of 2